Goldman Sachs’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-201,270
| Closed | -$63.7M | – | 5982 |
|
|
2023
Q4 | $63.7M | Buy |
201,270
+166,001
| +471% | +$32.3M | 0.01% | 1020 |
|
|
2023
Q3 | $5.96M | Sell |
35,269
-58,735
| -62% | -$11M | ﹤0.01% | 2831 |
|
|
2023
Q2 | $20.4M | Sell |
94,004
-72,119
| -43% | -$15.5M | ﹤0.01% | 1828 |
|
|
2023
Q1 | $30.2M | Sell |
166,123
-26,434
| -14% | -$5.06M | 0.01% | 1449 |
|
|
2022
Q4 | $37.8M | Buy |
192,557
+36,311
| +23% | +$7.79M | 0.01% | 1401 |
|
|
2022
Q3 | $35.1M | Sell |
156,246
-30,631
| -16% | -$6.2M | 0.01% | 1376 |
|
|
2022
Q2 | $23.6M | Buy |
186,877
+34,922
| +23% | +$4.01M | 0.01% | 1761 |
|
|
2022
Q1 | $19.3M | Buy |
151,955
+692
| +0.5% | +$77.9K | ﹤0.01% | 2072 |
|
|
2021
Q4 | $19.8M | Sell |
151,263
-635
| -0.4% | -$82.1K | ﹤0.01% | 2118 |
|
|
2021
Q3 | $18.6M | Sell |
151,898
-22,677
| -13% | -$2.62M | ﹤0.01% | 2132 |
|
|
2021
Q2 | $19.9M | Buy |
174,575
+25,441
| +17% | +$2.97M | ﹤0.01% | 2051 |
|
|
2021
Q1 | $17.9M | Buy |
149,134
+4,618
| +3% | +$523K | ﹤0.01% | 2025 |
|
|
2020
Q4 | $14.7M | Buy |
144,516
+52,591
| +57% | +$4.87M | ﹤0.01% | 2130 |
|
|
2020
Q3 | $7.11M | Buy |
91,925
+57,222
| +165% | +$4.88M | ﹤0.01% | 2612 |
|
|
2020
Q2 | $3.87M | Buy |
34,703
+18,459
| +114% | +$1.6M | ﹤0.01% | 2981 |
|
|
2020
Q1 | $1.17M | Buy |
16,244
+435
| +3% | +$37.2K | ﹤0.01% | 3644 |
|
|
2019
Q4 | $1.19M | Buy |
+15,809
| New | +$692K | ﹤0.01% | 4010 |
|
|
2019
Q3 | – | Sell |
-76,470
| Closed | -$1.53M | – | 5434 |
|
|
2019
Q2 | $1.53M | Buy |
+76,470
| New | +$1.53M | ﹤0.01% | 3701 |
|
Other funds holding KRTX
Goldman Sachs's KRTX Position: Q1 2024 in Review
Goldman Sachs sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 201,270 shares — an estimated $63.7M sold.
Goldman Sachs first reported a position in KRTX in Q2 2019 and held it in 18 quarters. The position peaked at $63.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- Goldman Sachs reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Goldman Sachs sold 201,270 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $63.7M.
- Goldman Sachs first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 18 quarters.
- Goldman Sachs's Karuna Therapeutics, Inc. Common Stock position peaked at $63.7M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.